Market Access News | pharmaphorum

News

Are RSV shots next in line for restrictions in the US?

After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.

News

FDA clears first gene therapy for rare genetic disease WAS

Fondazione Telethon's Waskyra has become the first gene therapy in the US for Wiskott-Aldrich syndrome, and the first taken to market by a non-profit.

News

UK confirms lower clawback rate for NHS medicines

The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."

News

Antibiotic is first approval in FDA national priority scheme

FDA approves its first 'national priority' drug – a version of the widely used antibiotic Augmentin XR – in double-quick time.

News

ASH: FDA okays Gamida aplastic anaemia therapy as data drops

The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA.

News

FDA reveals real-world pilot for digital health tools

The FDA is rolling out a pilot programme that could make it easier to bring digital health technologies for chronic diseases to market more quickly.

Are RSV shots next in line for restrictions in the US?

FDA clears first gene therapy for rare genetic disease WAS

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

ASH: FDA okays Gamida aplastic anaemia therapy as data drops

FDA reveals real-world pilot for digital health tools

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks